Review Article
Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy
Table 2
Studies reporting the changes of lipoprotein metabolism after DAA treatment.
| | Author | Country | Genotype | Treatment | Increase of total cholesterol during or after DAA treatment | Increase of LDL-C during or after DAA treatment | Increase of HDL- C during or after DAA treatment | Decrease of TG during or after DAA treatment |
| | Sun [67] | Taiwan | Genotype 1 | Sofosbuvir + ledipasvir or Grazoprevir + elbasvir | Yes | NA | NA | Yes |
| | Meissner [56] | USA | Genotype 1 | Sofosbuvir + ribavirin | NA | Yes | NA | Yes |
| | Chida [68] | Japan | Genotype 1b | Daclatasvir + asunaprevir | Yes | Yes | Yes | NA |
| | Endo [69] | Japan | Genotype 1b | Sofosbuvir + ledipasvir or daclatasvir + asunaprevir | Yes | Yes | Yes | NA |
| | Inoue [70] | Japan | Genotype 1b | Sofosbuvir + ledipasvir or Sofosbuvir + ribavirin or daclatasvir + asunaprevir | Yes | Yes | NA | Yes |
| | Chaudhury [66] | USA | Genotype 1 | Multiple DAA | Yes | Yes | NA | Yes |
| | Hashimoto [71] | Japan | Genotype 1 | Sofosbuvir + ledipasvir or daclatasvir + asunaprevir | NA | Yes | NA | NA |
| | Meissner [56] | USA | Genotype 1 | Sofosbuvir + ribavirin | Yes | Yes | NA | NA |
| | Townsend [72] | USA | Genotype 1 | Mostly sofosbuvir based | Yes | Yes | Yes | No |
| | Beig [65] | New Zealand | Mostly genotype 1 | Mostly sofosbuvir based | Yes | Yes | No | No |
| | Carvalho [73] | Portugal | Mostly genotype 1 | Mostly sofosbuvir based | Yes | Yes | No | No |
| | Gitto [74] | Italy | Mostly genotype 1 | Mostly sofosbuvir based | Yes | Yes | NA | NA |
| | Mauss [75] | Germany | Mostly genotype 1 | Multiple DAA | Yes | Yes | NA | NA |
| | Morales [58] | USA | Mostly genotype 1 | Only sofosbuvir based | Yes | Yes | NA | NA |
| | El Sagher [64] | Egypt | Genotype 4 | Sofosbuvir + simeprevir | Yes | Yes | Yes | NA |
| | Tran [54] | Multi- ethnic | Genotype 1 | Paritaprevir/ ritonavir + dasabuvir + ombitasvir | NA | NA | NA | Yes, also in patients with baseline elevated TG |
|
|
NA: not available, LDL-c: low density lipoproteins, HDL-c: high density lipoproteins, and TG: triglycerides.
|
